use substances without risk.
psychedelic(., psilocybin) entactogenic(, mdma) drug temporarily alter persons mood, thoughts, perceptions, lead heightened suggestibility, anxiety/ panic,/ paranoia, among outcomes.
psychedelics, participant experience vast changes perceptions reality, including time space.
moreover, individual become extremely sensitive internal external stimuli altered cognitive functioning visuoperceptual skills.
knowing realities, therapy uses psilocybin mdma, example, involve thorough participant screening, education, preparation, supportive settings, close supervision credentialed qualified medical mental health professionals maximize safety promote potential therapeutic outcomes( davis et al., 2021; johnson et al., 2008; nichols, 2016; phelps, 2017).
furthermore, acknowledging suggested therapies could potentially lead blurring ethical boundaries participants provider() cases, well potential enhanced suggestibility, might increased risk serious intimate ethical boundary violations session facilitators/ monitors, including emotional, physical, sexual abuse( anderson,., danforth,., grob,., 2020; goldhill, 2020; pilecki et al., 2021), though psychedelics entactogens means unique regard.
populations might higher risk adverse reactions psychedelic entactogenic drugs, people known history serious cardiac conditions serious mental conditions borderline personality disorder bipolar disorder( bender hellerstein, 2022; bradberry et al., 2022; leonard et al., 2018; lim et al., 2012; malcolm thomas, 2021).
given broad array potential challenges therapies may use psychedelics(, psilocybin) entactogens(, mdma), compounded absence consensus best address challenges, proactive collaborative approach may effective, partnership subject matter expertise consolidate efforts collectively work address relevant issues( belouin et al., 2022; belouin henningfield, 2018; xi et al., 2023).
best practices good, credentialling, et. letter seeks broad input address five major landscape domains may contribute developing real- world risk reduction mitigation frameworks protect public health safety considering implementing potential therapies use psychedelic entactogenic drug substance medically supervised interpersonally supportive settings.
include:() service delivery,() promoting participant protections,() engagement communities,() safeguarding equitable access,() best practices data standards.
service delivery spectrum interdisciplinary practitioners held accountable session facilitators/ monitors potential use substances medically supervised interpersonally supportive settings?
training considerations minimal training standards integrated care delivery?
curriculum needed best addresses variations psychotherapy(, best address participants vulnerability manage psychedelic- related challenging experiences)?
credentialing considerations relevant background education, qualifications, professional experiences, potential examinations might considered interdisciplinary credentialing?
disciplines may represent` service providers(, clinical practitioners, counselors, peer support)?
might appropriate supervision practice hour requirements?
types guidance documents may necessary provide close supervision/ monitoring participants using psychedelics entactogens?
promoting participant protections provide input strategies may critical protecting participants, including: strategies needed ensure participant education, screening medical mental health conditions may disqualify participation, informed consent prior individual participating therapy may use psychedelic entactogenic drug substance?
needed assess baseline pre- dose adverse event monitoring post-
dose(, suicidal ideation behavior, physiological reactions, psychological harm, substance misuse, drug- drug interactions)?
information available needed medically supervised interpersonally supportive settings might incorporate substance misuse screening prevention, risk mitigation, safety ethical monitoring strategies protect participants potential ethical boundary violations providers?
components need developed support ethical- vigilance reporting systems(, state departments consumer protection, professional societies, state licensing bodies, law enforcement)?
data might collected improves existing pharmacovigilance reporting systems?
strategies complement existing patient protection regulations enforced fda reduce risk clinical trial participants well users approved regulated products?
engagement communities path caucus invites input help identify best mechanisms/ approaches achieve engagement diverse communities, including: might indigenous peoples use psychedelics(, ayahuasca, peyote) sacraments spiritual ceremonial ritual healing practices, improve understanding protect public health safety?
might ensure engagement vulnerable populations disproportionately affected mental health conditions, including people experiencing homelessness, racial/ ethnic minorities, sexual gender minorities, older adults, people living disabilities chronic health conditions, individuals criminal justice system( ortiz et al., 2022)?
examples best practices facilitate provider(, clinical practitioners, counselors, peer support) engagement vulnerable populations?
effectively navigate societal stigma associated psychedelic entactogenic use?
effectively educate healthcare, local crisis response systems, law enforcement?
best engage comprehensive transparent community educational outreach?
safeguarding equitable access considered critical elements development capabilities across following domains activities?
reimbursements ensure equitable access services.
healthcare economic impact analyses.
types medically supervised interpersonally supportive therapy settings.
collaboration activities may include input prescribing, administering, dispensing.
manufacturing distribution standards.
supporting oversight available supply substances.
diversion control monitoring.